Compare iShares MSCI Taiwan ETF (EWT) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Taiwan ETF vs Sana Biotechnology Inc — how do they compare? iShares MSCI Taiwan ETF trades at $106.2, while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: iShares MSCI Taiwan ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| EWT | SANA | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $111.53 | $5.92 |
52-Week Low | $58.05 | $2.68 |
Market Cap | — | $1.13B |
Enterprise Value | — | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWT (iShares MSCI Taiwan ETF) trades at $106.19, up 3.92% with strong bullish momentum from moving averages. The ETF benefits from Taiwan's AI-driven semiconductor exposure, particularly through TSMC's 22.5% weighting. Recent news highlights continued capital flows into Taiwan's tech sector despite regional volatility, with MediaTek and ASE Technology announcing significant AI-related investments.
Outlook remains positive given Taiwan's leadership in semiconductor manufacturing and AI supply chain dominance. Key risks include geopolitical tensions with China and potential rotation away from AI-heavy markets. Institutional sentiment appears constructive with selective foreign inflows supporting the ETF's premium valuation.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Taiwan ETF
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
